Explained: ICMR’s ambitious timeline to launch COVID-19 vaccine and controversy
India’s apex medical research body has announced that the country should have its coronavirus vaccine ready in time for Independence Day on August 15. However, experts notwithstanding ICMR’s ambitious timeline have questioned how all three phases can be concluded within a month and a half.By A. AhmadOn July 3, the Indian Council of Medical Research (ICMR) announced that it would launch the indigenous COVID-19 vaccine for public use by August 15 after completion of clinical trials. India’s national broadcaster Prasar Bharati News Service tweeted about it.The ICMR has selected 12 institutes for ...
How to volunteer for a COVID-19 vaccine study
Interested in volunteering to receive an experimental vaccine for COVID-19?The COVID-19 Prevention Network, which is funded by the National Institute of Health, launched a website for people in the United States looking to volunteer for clinical trials as a few vaccines are ready for phase 3.Phase 3 is meant to determine how likely it is the vaccine prevents new infections, so the best candidates will be people who haven’t already been exposed to the virus but are at high risk to contract the coronavirus (COVID-19). Earlier trials used smaller groups and were used to determine the proper dose ...
Experts say side effect of COVID-19 vaccine tolerable, dismiss pessimism of West media reports
Photo:XinhuaDespite skepticism and pessimism from Western media, vaccine experts advised the public not to panic over the side effects revealed in the preliminary results of a Chinese-developed coronavirus vaccine as the adverse reactions exposed are tolerable and the vaccine is under constant optimization.The appeal came after some Western media hyped the side effect ratio reported in early-stage clinical trials of the Ad5-nCoV recombinant novel coronavirus vaccine.The vaccine against COVID-19, jointly developed by a military research team and Chinese biopharmaceutical firm CanSino Biologics,...
US awards $1.6 billion to Novavax for COVID-19 vaccine
Washington (AFP) - The US on Tuesday announced it was providing $1.6 billion in funding for the development and manufacture of a COVID-19 vaccine candidate produced by biotech firm Novavax, the largest amount awarded under Operation Warp Speed.Separately, the US also said it was providing $450 million to Regeneron for its experimental COVID-19 treatment and prophylaxis, a combination of two antibodies.Under the terms of its agreement with the Department of Health and Human Services (HHS) and Department of Defense, Novavax agrees to deliver 100 million doses of its vaccine, potentially by the e...
US FDA commissioner refuses to offer COVID-19 vaccine timing
WASHINGTON - Commissioner of the US Food and Drug Administration (FDA) Stephen Hahn on Sunday refused to offer a timeline for COVID-19 vaccine, which US President Donald Trump suggested could be available "long before the end of the year.""I can't predict when a vaccine will be available," Hahn told ABC on Sunday. "We are seeing unprecedented speed for the development of a vaccine. But ... our solemn promise to the American people is that we will make a decision based upon the data and science on a vaccine, with respect to the safety and effectiveness of that vaccine."During a Fourth of July a...
China Daily US edition
Are Ugandan scientists close to getting Covid-19 vaccine?
Governments worldwide are working hard to revive their economies and return to the old normal, with an effective vaccine or drug against Covid-19 as their enabling tool.With more than 10.5 million coronavirus confirmed cases and over half a million deaths reported globally in seven months, various people are trying to navigate their way out.Although there have been concerns that a number of leaders in Africa, including Uganda, are using the pandemic as their cash cow and that some of the directives to curb the spread of the virus are insensitive to community needs, the deadliness of the diseas...
Another experimental covid-19 vaccine has shown promising early resultsCharlotte Jeeon July 2, 2020 at 11:18 am
The news: An experimental covid-19 vaccine being developed by Pfizer and BioNTech provoked immune responses in 45 healthy volunteers, according to a preprint paper on medRXiv. The levels of antibodies were up to 2.8 times the level of those found in patients who have recovered. The study randomly assigned 45 people to get either one of three doses of the vaccine or a placebo. But there were side effects like fatigue, headache, and fever–especially at higher doses. The researchers decided to discontinue with the highest dose, 100 micrograms, after the first round of treatments.Some caveats requ...
BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial
FRANKFURT - A COVID-19 vaccine developed by German biotech firm BioNTech and U.S. pharmaceutical giant Pfizer has shown potential and was found to be well tolerated in early-stage human trials, the companies said on Wednesday.The drug is one of 17 being tested on humans in a frantic global race to find a vaccine the world is counting on to end a pandemic that has infected 10.5 million people and killed more than half a million so far.The potential treatment is the fourth early-stage COVID-19 drug to show promise in human testing, along with projects involving Moderna, CanSino Biologics and Ino...
Jpost.com - The Jerusalem Post online edition
URGENT: Anges starts Japan's 1st COVID-19 vaccine clinical test on humans
Medical startup Anges Inc. said Tuesday it has started Japan's first clinical test on humans of a potential vaccine for the new coronavirus at an Osaka hospital.The test at Osaka City University Hospital will run through July 31, 2021, Anges said. It has said it aims to earn the government's authorization to manufacture and sell the DNA vaccine by the spring to fall of next year.In the test, Anges will divide healthy adults into two teams of 15, with one group being injected with larger amounts of the vaccine than the other. Each person will receive two intramuscular shots of the vaccine two w...
CanSino's recombinant COVID-19 vaccine approved as special military drug
A staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd., in Beijing, capital of China, March 16, 2020. (Xinhua/Zhang Yuwei)Chinese biopharmaceutical firm CanSino Biologics Inc announced on Monday that a recombinant novel coronavirus vaccine (Ad5-nCoV) the company developed with a military research team has received special one-year military drug approval.The approval for the military use of Ad5-nCoV was granted by the Health Bureau of the Logistics Support Department of the Central Military Commission on June 25, for one year, the company said in a statement...